Literature DB >> 28365794

Response: Randomised trial of the effect of a gastrin/CCK2 receptor antagonist on esomeprazole-induced hypergastrinaemia: evidence against rebound hyperacidity.

Malcolm Boyce1, Frans van den Berg2, Toni Mitchell2, Kate Darwin2, Steve Warrington2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28365794     DOI： 10.1007/s00228-017-2241-3

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  4 in total

1.  Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial.

Authors:  E Björnsson; H Abrahamsson; M Simrén; N Mattsson; C Jensen; P Agerforz; A Kilander
Journal:  Aliment Pharmacol Ther       Date:  2006-09-15       Impact factor: 8.171

2.  Randomised trial of the effect of a gastrin/CCK2 receptor antagonist on esomeprazole-induced hypergastrinaemia: evidence against rebound hyperacidity.

Authors:  Malcolm Boyce; Frans van den Berg; Toni Mitchell; Kate Darwin; Steve Warrington
Journal:  Eur J Clin Pharmacol       Date:  2016-10-29       Impact factor: 2.953

3.  Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects.

Authors:  Malcolm Boyce; Sally Dowen; Gillian Turnbull; Frans van den Berg; Chun-Mei Zhao; Duan Chen; James Black
Journal:  Br J Clin Pharmacol       Date:  2015-05       Impact factor: 4.335

Review 4.  Potential clinical indications for a CCK2 receptor antagonist.

Authors:  Malcolm Boyce; Katie A Lloyd; D Mark Pritchard
Journal:  Curr Opin Pharmacol       Date:  2016-10-03       Impact factor: 5.547
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.